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Key points 
In successfully treated HIV-disease the prevalence of cognitive impairment is 
approximately 20%, which is lower than previous reports. Advanced neuroimaging 
suggests that white matter microstructural abnormalities rather than grey or white 
matter volume abnormalities are the likely underlying aetiology. 
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Long-term comorbidities such as cognitive impairment remain prevalent in otherwise 
effectively treated people-living-with-HIV. We investigate the relationship between 
cognitive impairment and brain structure in successfully treated patients using multi-
modal neuroimaging from the Co-morBidity in Relation to AIDS (COBRA) cohort. 
 
Methods 
Cognitive function, brain tissue volumes and white matter microstructure were 
assessed in 134 HIV-positive patients and 79 controls. All patients had suppressed 
plasma HIV RNA at cohort entry. In addition to comprehensive voxelwise analyses of 
volumetric and diffusion tensor imaging, we used an unsupervised machine learning 
approach to combine cognitive, diffusion and volumetric data, taking advantage of the 
complementary information they provide. 
 
Results 
Compared to the highly comparable control group, cognitive function was impaired in 
four out of the six cognitive domains tested (median global T-scores: 50.8 vs. 54.2, 
p<0.001). Patients had lower grey but not white matter volumes, observed principally 
in regions where structure generally did not correlate with cognitive function. 
Widespread abnormalities in white matter microstructure were also seen, including 
reduced fractional anisotropy with increased mean and radial diffusivity. In contrast 
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to the grey matter, these diffusion abnormalities correlated with cognitive function. 
Multivariate neuroimaging analysis identified a neuroimaging phenotype associated 
with poorer cognitive function, HIV-infection and systemic immune activation.  
 
Conclusions 
Cognitive impairment, lower grey matter volume and white matter microstructural 
abnormalities were evident in HIV-positive individuals despite fully suppressive 
antiretroviral therapy. White matter abnormalities appear to be a particularly 
important determinant of cognitive dysfunction seen in well-treated HIV-positive 
individuals. 
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Introduction  
As a result of modern combination antiretroviral therapy, HIV-infection is now a 
chronic disease with life expectancy approaching that of the general population [1]. 
Despite this, concerns remain regarding an increased prevalence of age-associated 
comorbidities and the possibility of an ‘accelerated ageing’ phenotype [2]. Cognitive 
impairment, which is associated with poorer clinical outcomes and higher mortality 
[3,4] reportedly affects up to 50% of HIV-positive individuals [5,6]. Yet, most data 
does not pertain to virologically suppressed cohorts, which are now the norm in 
Northern European settings [7] and hence there remains uncertainty about its 
aetiology. 
 
One possibility is that cognitive impairment results from structural damage to brain 
regions that support cognition. Earlier work has described lower grey and white 
matter volumes in numerous locations in HIV-positive individuals [8-13]. Diffusion-
weighted imaging, an advanced MRI technique, is more sensitive at revealing white 
matter abnormalities than volumetric measures in HIV-positive individuals [14-19]. 
However, the relationships between imaging abnormalities and cognitive function 
remain uncertain, particularly in well-treated patients, with several studies failing to 
report any associations [13,17,19,20]. 
 
Given the advances in HIV-medicine and neuroimaging techniques we recruited 
virally suppressed HIV-positive individuals and a demographically comparable HIV-
negative control group into the EU-funded Co-morBidity in Relation to AIDS 
(COBRA) study. We determined the prevalence of cognitive impairment and its 
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relationships with grey and white matter abnormalities. Furthermore, we 
systematically investigated whether previously proposed sub-types of HIV-associated 
brain injury [21] were present using a multi-modal, ‘machine-learning’ approach. We 
tested the following hypotheses: i) despite successful antiretroviral therapy, HIV-
positive individuals would exhibit cognitive impairment compared to an appropriate 
HIV-negative control population; ii) HIV-positive individuals would have lower grey 
and white matter volumes as well as multiple abnormalities on diffusion-weighted 
imaging; iii) cognitive impairment would be associated with abnormal brain structure; 
and iv) grey and white matter abnormalities would occur together and more 
commonly in HIV-positive individuals supporting the presence of a common 
pathogenic mechanism.  
Methods  
Participants 
In total, 134 HIV-positive participants were recruited to the COBRA study from 
London (n=59) and Amsterdam (n=75). For a graphical illustration of the methods see 
supplementary figure 1. A demographically comparable HIV-negative control 
population was recruited from sexual health clinics and specific community groups 
(London: n=29; Amsterdam: n=50). Eligible participants were aged ≥45 with no 
significant neurological conditions, substance/alcohol abuse or moderate/severe 
depression (see supplementary data for specific exclusion criteria). All HIV-positive 
participants had to have plasma HIV RNA <50 copies/mL on antiretroviral therapy 
for >12 months prior to enrolment.  
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This study was approved by the institutional review board of the Academic Medical 
Center (AMC) (NL 30802.018.09) and a UK Research Ethics Committee (REC) 
(13/LO/0584 Stanmore, London). All participants provided written informed consent. 
 
Neuropsychological tests 
Participants completed a comprehensive neuropsychological test battery, assessing 
attention, executive function, language, memory, information processing speed and 
motor function (supplementary table 1). Raw scores were converted to standardised 
T-scores accounting for age and educational level with higher T-scores representing 
better cognitive function. Global T-score was the mean of the six domain T-scores. 
Three common classification methods, the HIV-associated neurocognitive disorder 
(‘Frascati’) criteria, the global deficit score (GDS) and multivariate normative 
comparison (MNC) were then applied according to published methods [22-24]. 
 
Neuroimaging acquisition 
In London, images were acquired using a Siemens 3T Verio scanner with a 32-
channel head coil (HIV-positive: n=59; HIV-negative: n=29) and in Amsterdam 
initially with a Philips 3T Intera with an 8-channel phased array head coil (HIV-
positive: n=46; HIV-negative: n=20) and then using a Philips 3T Ingenia with a 16-
channel head coil (HIV-positive: n=29; HIV-negative: n=30; both Philips Healthcare, 
Best, the Netherlands) due to a scanner upgrade (see supplementary data for scanning 
parameters). 
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Image processing 
T1-weighted images were pre-processed using SPM12 (University College London, 
London, UK).  Briefly, images were bias corrected, segmented into grey matter, white 
matter and cerebrospinal fluid (CSF) and volumes calculated. These were then 
registered to a custom template and normalised to Montreal Neurological Institute 
(MNI)-152 space using the Diffeomorphic Anatomical Registration using 
Exponentiated Lie algebra (DARTEL) algorithm [25].  
 
Diffusion data were pre-processed using FMRIB Software Library v5.0.6 (FSL, 
FMRIB, University of Oxford). Briefly, images were corrected for eddy currents and 
head motion, non-brain tissue was deleted and the diffusion tensor model was fitted at 
every voxel. These were then registered to a custom template and standard space, 
using Diffusion Tensor Imaging ToolKit v2.3.1 [26]. Fractional anisotropy (FA), 
axial, mean and radial diffusivity maps for each participant were then ‘skeletonised’ 
using FSL and thresholded using FA 0.2 to exclude areas with considerable inter-
individual variability prior to performing tract-based spatial statistics (TBSS) [27]. 
 
Statistical analyses 
Group comparisons  
Baseline group differences were assessed using chi-square, Fisher’s exact, Wilcoxon 
rank sum and unpaired t-tests as appropriate. To account for variance associated with 
potential scanner and head coil differences, a three-level factor was entered into all 
models, an approach used previously in multisite studies of HIV-positive individuals 
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[8,20]. These analyses were performed using R v3.1.3, with p-values <0.05 
considered statistically significant.  
 
Voxelwise inference testing  
Voxelwise group differences in grey and white matter volume and diffusion measures 
were calculated using the general linear model, adjusting for age, intracranial volume 
and scanner. Correction for multiple comparisons used permutation testing [28] 
(n=10,000) and threshold-free cluster enhancement (TFCE) [29]. Permutation-
corrected p-values <0.05 were considered significant. 
 
Combining imaging and cognitive data 
For each cognitive domain, a multiple linear regression model was fitted with age, 
intracranial volume, scanner, HIV-status and either total grey matter volume or mean 
skeleton FA as independent variables and the relevant cognitive domain T-score as 
the dependent variable. Separate models with an additional HIV-status and imaging 
measure interaction term were also tested. To investigate the relationship between 
localised brain structure and cognitive function, voxelwise regressions were 
calculated using similar methods.  
 
Cluster analysis 
T1-weighting provides good contrast between grey and white matter for volumetric 
assessment, whereas diffusion-weighting provides information about white matter 
microstructure. To take advantage of this complementary information we used 
multivariate k-means clustering to test whether distinct groups could be identified 
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based on neuroimaging measures. As a dimension reduction step, each participant’s 
brain was summarised into 109 regions using the Harvard-Oxford and International 
Consortium of Brain Mapping (ICBM) DTI-81 atlases. To ensure comparable 
distributions, these were then scaled before entering into the clustering model. To 
assess the optimal number of clusters, separate models with 2-10 clusters were 
calculated. These were compared using the Calinski-Harabasz index and the average 
silhouette width. The Duda-Hart test was used to confirm cluster structure to the data 
(i.e., k>1). Cluster stability was assessed using the Jaccard coefficient, calculated 
using bootstrapping with 10,000 resamples [30]. Cluster analyses were performed 
with the R package ‘fpc’ v2.1.9. 
Results  
Participants 
At entry, all HIV-positive participants (n=134) had an undetectable plasma HIV RNA 
with a median (interquartile range) CD4+ cell count of 618 (472-806) cells/µL and 
duration of antiretroviral therapy of 12.5 (7.4-16.9) years. The HIV-negative group 
(n=79) was comparable to the HIV-positive group in: age, gender, education level, 
cardiovascular risk factors, smoking and recreational drug use. The HIV-positive 
group included a greater proportion of Black-Africans (table 1). One participant did 
not complete the full cognitive battery, and neuroimaging data was missing for n=5 
participants (T1 not useable n=1, incomplete diffusion-MRI n=1, excessive motion 
artefact on diffusion-MRI n=3). 
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Cognitive function 
Cognitive impairment was more prevalent in the HIV-positive group, regardless of 
the method used: GDS: 18.0% vs. 3.8% (odds ratio [95% confidence interval] 5.58 
[1.86-24.1], p<0.01); Frascati: 18.0% vs. 3.8% (5.58 [1.86-24.1], p<0.01); MNC: 
19.5% vs. 2.5% (9.36 [2.68-59.2], p<0.001). The HIV-positive group scored lower 
than the control group in the domains of attention, executive function, motor function 
and processing speed (Fig. 1, W210>6300 and p0.01 for all). Only 1.5% of the HIV-
positive group and 1.2% of controls fulfilled the criteria for HIV-associated dementia.  
 
Brain tissue volumes and diffusion measures 
HIV-positive individuals had lower total grey matter volume than controls (table 2). 
There was a significant negative correlation between age and grey matter volume (r=-
0.31, p<0.0001) but no significant age and HIV-status interaction (t205=0.45, p=0.65). 
Voxelwise analysis demonstrated lower grey matter volume in the HIV-positive 
group, located principally in the intracalcarine and supracalcarine cortices (Fig. 2). In 
contrast, total white matter volume was not significantly different between the groups 
(p=0.59), nor were there any significant voxelwise differences.  
 
Despite comparable white matter volumes, HIV-positive individuals had lower FA 
and higher mean and radial (but not axial) diffusivity than controls (table 2). There 
were age-associated changes to all diffusion metrics (r=-0.36, 0.45, 0.45 and 0.40 for 
FA, mean, radial and axial diffusivity respectively, p<0.0001 for all) but no 
significant interactions between age and HIV-status (p>0.5 for all). Voxelwise 
analyses revealed widespread abnormalities in FA, mean and radial diffusivity in 
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HIV-positive individuals with a similar pattern of change to the whole brain diffusion 
metrics (Fig. 2).  
 
In the HIV-positive group, grey and white matter volumes and mean FA were not 
associated with known duration of untreated HIV-infection, duration of antiretroviral 
therapy, current or nadir CD4+ cell counts or CD4+:CD8+ cell count ratio (p>0.15 for 
all). However, there were trends for patients with prior AIDS to have lower grey 
matter volume (difference 14.3 mL, t128=1.9, p=0.06) and lower mean FA (difference 
0.0059, t128=1.7, p=0.08).  
 
HIV-associated brain injury and cognitive function 
Across patients and controls, larger grey matter volumes were associated with better 
cognitive performance. Total grey matter volume was positively correlated with 
executive function, motor function and global T-scores with no significant 
interactions between HIV-status and cognitive T-scores (table 3). Voxelwise analyses 
were then performed allowing regional differences in the relationship between brain 
structure and cognition to be explored. Spatial correspondence between the regions of 
grey matter correlated with cognitive function and the previously described HIV-
associated grey matter volume reduction was generally modest, but greatest for 
executive function (Fig. 3, supplementary table 2).  
 
Across both groups, higher FA was associated with greater cognitive performance. 
FA averaged across the main white matter tracts was positively correlated with 
attention, executive function, processing speed and global T-scores (table 3). There 
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were no interactions between HIV-status, FA and cognitive T-scores. Across both 
groups, using a voxelwise approach, FA was positively correlated with attention, 
executive function, motor function and processing speed and global T-scores in many 
regions, primarily in the body and genu of the corpus callosum. In contrast to the grey 
matter volume results, these were similar to white matter tracts with reduced FA in 
the HIV-positive group (Fig. 3, supplementary table 2).  
 
Cluster analysis 
Using k-means clustering, two groups were identified that were stable with 
resampling (mean Jaccard coefficient 0.99). Other cluster models (i.e. k>2) were 
much less stable (mean Jaccard coefficient <0.7). In the two-cluster model, cluster 
one (n=99) had higher grey matter volume and higher mean FA in all regions, 
whereas cluster two (n=109) had lower grey matter volume and lower mean FA in all 
regions. HIV-positive individuals were more likely to be members of cluster two, 
61.2% vs. 36.4% (odds ratio 2.74 [1.53-4.98], p<0.001, Fig. 4). Furthermore, subjects 
in cluster two were older (median 59.3 vs 54.6 years, W206=3634, p<0.001) and had 
significantly poorer cognitive function in the domains of attention, executive function, 
motor function and processing speed (Fig. 5, W205≥6307, p≤0.03 for all). Importantly, 
these cognitive differences between members of clusters one and two were not due to 
demographic differences, as the cognitive T-scores are adjusted for age and 
educational level. Although there were no significant differences in current and nadir 
CD4+ cell counts (p=0.10 and 0.17), HIV-positive individuals in cluster two had 
lower CD4+:CD8+ ratios (0.82 vs. 1.06, W132=2666, p=0.01) and were older (58.6 vs 
53.2 years, W132=1380, p<0.001) than those in cluster one. 
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Discussion 
We demonstrate that HIV-positive individuals have evidence of cognitive 
impairment, lower grey matter volume and widespread white matter microstructural 
abnormalities despite successful antiretroviral treatment. Generally, the grey matter 
volume reduction associated with HIV-infection was modest and did not occur in 
regions where brain structure correlated with cognitive function. In contrast, HIV-
associated white matter abnormalities were widespread and found in many of the 
white matter tracts whose structure correlated with cognitive function. These findings 
extend previous work [13,17,19,20] by showing that white matter structure is 
correlated with cognitive impairment in chronic HIV-infection. Our findings suggest 
that the pathophysiology of cognitive impairment in treated HIV-disease is 
predominantly due to white matter microstructural injury and support the use of FA as 
a biomarker to identify HIV-associated brain injury. Furthermore, we consistently 
showed a lack of interaction between HIV-status, age and neuroimaging biomarkers 
which suggests static rather than active brain injury in well-treated patients. However, 
longitudinal data are required to confirm this. 
 
The prevalence of cognitive impairment in well-treated HIV-positive patients has 
been uncertain. Although early studies reported high rates of cognitive impairment in 
chronically treated patients [5,6,31], some studies have failed to observe this [32]. In 
our study, both study groups were high performing with nearly 40% having some 
form of tertiary education, which may explain the relatively low prevalence of 
cognitive impairment. Furthermore, the use of methods less likely to classify high 
numbers of individuals with cognitive impairment such as MNC [33], in comparison 
with a demographically-comparable control group and sustained suppression of 
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viraemia in the patient group are likely to have contributed to the relatively low 
prevalence of HIV-associated cognitive impairment.  
 
Total grey matter volume was lower in the HIV-positive group with reductions 
occurring primarily in the intracalcarine and supracalcarine cortices. Previous studies 
in populations with variable suppression of HIV-replication have described more 
widespread grey matter volume reductions [8,10,12]. However, the locations where 
we observed abnormalities are consistent with regions of greatest neuronal [34] and 
grey matter volume [11] loss observed in untreated HIV-infection. Together with the 
trend for those with prior AIDS to have the lowest grey matter volume, our findings 
suggest these regions are the earliest affected during the course of HIV-infection and 
that further atrophy may be prevented with successful treatment.  
 
Diffusion-weighted imaging showed widespread evidence of HIV-associated white 
matter microstructural injury, with the disparity in radial but not axial diffusivity 
suggestive of white matter demyelination [35]. The characteristics and location of this 
injury are consistent with histopathological reports from the pre-antiretroviral era, 
where myelin damage was found in the central white matter [36]. The decoupling of 
diffusion abnormalities and white matter atrophy is interesting and has been reported 
previously in HIV-positive individuals with relatively preserved immunity (mean 
CD4+ 613 cells/uL) [17]. Together with the trend for the most severe abnormalities to 
occur in patients with prior AIDS, our findings suggest that diffusion abnormalities 
may reflect historical damage prior to antiretroviral therapy initiation and that 
progression to white matter atrophy may be aborted with sustained suppression of 
HIV-replication. Although cardiovascular disease may also be implicated in well-
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treated patients [37], this is unlikely to explain the observed group differences, given 
the similarity in measured cardiovascular risk factors between groups. As we report 
cross-sectional data, we are unable to resolve the issue of whether these imaging 
changes reflect historical damage or an on-going pathological process.  
 
The HIV-associated microstructural injury occurred in white matter tracts correlated 
with cognitive function. In contrast, the HIV-associated grey matter volume reduction 
generally did not occur in brain regions correlated with cognitive function. Although 
this could reflect the cognitive battery we employed, these data suggest that white 
matter abnormalities may be a more important determinant of cognitive impairment in 
treated HIV-disease. White matter abnormalities of this type  correlate with cognitive 
function in other disease states [38], and are thought to disrupt the synchronised 
functioning of large-scale, distributed brain networks that cognition depends on.  
 
Using a multivariate approach to examine individual differences in volumetric and 
diffusion data simultaneously, we identified a brain phenotype that was associated 
with ageing, cognitive dysfunction, and HIV-status. Furthermore, this phenotype was 
associated with lower CD4+:CD8+ ratios.  This biomarker of immune activation has 
previously been associated with other age-related comorbidities in well-treated 
cohorts [39]. Our findings suggest that persistent immune activation may also be 
associated with brain injury, which may reflect the legacy of prolonged untreated 
infection as normalisation of this ratio has been associated with earlier antiretroviral 
therapy initiation [40]. 
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Our study benefits from comprehensive neuropsychological, volumetric and diffusion 
assessments in patients and demographically-appropriate controls. However, our 
study has a number of limitations. Whilst our cohort is not representative of the entire 
HIV-positive population, it is representative of older HIV-positive adults receiving 
care in a Northern European setting where over 90% are successfully treated [7]. 
Cohort studies are potentially limited by unmeasured differences confounding group 
comparisons. This is particularly an issue when studying HIV-positive populations 
and age-related comorbidities given high rates of smoking, alcohol and recreational 
drug use. We limited this by recruiting a comparable control population but 
unmeasured differences between the two groups may remain. One previous study of 
virally suppressed patients [41], which used different MRI modalities, may have had a 
less comparable control group (81% of the HIV-positive group vs 47% of the HIV-
negative group were male), which may lead to an overstatement of the HIV 
association. Differences in scanner and head coil parameters between sites may 
potentially confound multi-site neuroimaging studies, however, bias was minimised 
by adjusting for these factors in our models. Furthermore, restricting the analyses to 
data acquired in London only resulted in HIV associations of a similar magnitude and 
direction as the entire study population (supplementary table 3), giving confidence 
that scanner differences did not bias our main findings. Cluster analysis may split the 
participants into potentially arbitrary groups and the ‘good’/’bad’ brain phenotype 
may, in reality, be more of a continuum. Although exploratory, we found excellent 
internal validity by demonstrating a high level of cluster stability with resampling and 
good external validity by the associations of cluster membership with age, HIV-status, 
cognitive function and markers of systemic immune activation.  
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To conclude, HIV-infection was associated with both lower grey matter volume and 
white matter microstructural injury. Cognitive impairment, present in approximately 
20% of cases, was most clearly associated with white matter abnormalities. Grey and 
white matter abnormalities tended to occur together suggesting a common aetiology 
for HIV-associated brain injury, which may be related to prolonged untreated 
infection and immune activation, in common with other non-AIDS comorbidities. 
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Tables titles and legends 







Age (years), median (IQR) 55 (51, 62) 57 (52, 64) 0.24 
Gender, n (%)   0.79 
Female 9 (6.7%) 6 (7.6%)  
Male 125 (93.3%) 73 (92.4%)  
Ethnicity, n (%)   0.03 
Black-African 16 (12.0%) 2 (2.6%)  
White 117 (88.0%) 76 (97.4%)  
Sexuality, n (%)   0.45 
MSM 104 (77.6%) 59 (74.7%)  
Bisexual 10 (7.5%) 4 (5.1%)  
Heterosexual  18 (13.4%) 16 (20.2%)  
Years of education, median (IQR) 14 (13-16) 16 (14-17) 0.23 
Cardiovascular disease, n (%)    
Hypertension 56 (42.1%) 30 (38.5%) 0.66 
Myocardial infarction 2 (1.5%) 3 (3.8%) 0.36 
Type 1 diabetes 0 (0%) 0 (0%) N/A 
Type 2 diabetes 10 (7.5%) 5 (6.3%) 1.00 
BMI (kg/m2), median (IQR) 24.6 (22.6-27.4) 24.6 (23.3-28.4) 0.30 
Total cholesterol (mmol/L), median (IQR) 5.28 (5.11-5.45) 5.33 (5.11-5.55) 0.51 
HDL cholesterol (mmol/L), median (IQR) 1.26 (1.07-1.50) 1.30 (1.07-1.57) 0.51 
LDL cholesterol (mmol/L), median (IQR) 2.99 (2.83-3.16) 3.14 (2.83-3.16) 0.30 
Triglycerides (mmol/L), median (IQR) 1.70 (1.15-2.53) 1.51 (1.07-2.25) 0.20 








Never smoked 36 (26.9%) 30 (38.0%)  















Use of recreational drugs in past 6 months, n (%) 44 (32.8%) 18 (22.8%) 0.16 
CD4+ count (cells/µL), median (IQR)  618 (472-806) 900 (692-1174) <0.01 
CD4+:CD8+ cell count ratio, median (IQR) 0.84 (0.60-1.12) 2.01 (1.44-2.64) <0.01 
Nadir CD4+ count (cells/µL), median (IQR) 180 (90-250) N/A  
Years since HIV diagnosis, median (IQR) 15.0 (9.1-20.0) N/A  
Duration of antiretroviral therapy (years), median (IQR) 12.5 (7.4-16.9) N/A  
HIV RNA viral load < 200 copies/mL, n (%) 134 (100%) N/A  
Prior clinical AIDS, n(%) 42 (31.3%) N/A  
Likely route of HIV transmission, n (%)  N/A  
MSM 115 (85.8%)   
Heterosexual sex 15 (11.2%)   
IVDU/Blood product 1 (0.8%)   
Unknown 3 (2.2%)   
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P-values calculated using the chi-squared test, Fisher’s exact and Wilcoxon rank sum 
tests as appropriate. Hypertension was defined by either: three measurements of 
systolic BP ≥140 mmHg; three measurements of diastolic BP ≥90 mmHg or use of 
blood pressure lowering medication. Abbreviations: HDL – high-density lipoprotein, 
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Table 2. Volumetric and diffusion imaging measurements. 
 
Volumetric measures 
Imaging measure HIV-positive HIV-negative Difference (95% CI) t206 p-value 
Grey matter volume (mL) 659 673 13.7 (2.3-25.1) 2.37 0.02 
White matter volume (mL) 479 476 2.4 (-6.4-11.2) -0.54 0.59 
 
Diffusion measures 
Imaging measure HIV-positive HIV-negative Difference (95% CI) t202 p-value 
Fractional anisotropy 0.477 0.484 0.007 (0.002-0.012) 2.92 <0.01 
Mean diffusivity (mm2/s) 705 696 8.5 (1.2-15.8) -2.27 0.02 
Radial diffusivity (mm2/s) 503 493 10.3 (2.7-17.9) -2.66 <0.01 
Axial diffusivity (mm2/s) 1,108 1,103 4.9 (-2.5-12.3) -1.31 0.19 
 
Least squares means, a potentially better estimate of the true population mean for 
each neuroimaging measure by HIV-status and 95% confidence intervals (CI) – 
adjusted for age, intracranial volume and scanner type. Subscript indicates degrees of 
freedom for the t-statistic. 
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Table 3. Associations between cognitive function and imaging parameters. 
 
 Grey matter volume regression estimate  
(T-score/mL) 
 HIV-grey matter 
interaction 
Cognitive domain Estimate  (95% CI) p-value  t203 p-value 
Attention 0.035 (-0.001-0.072) 0.06  1.91 0.06 
Executive function 0.041 (0.013-0.068) <0.01  0.75 0.45 
Memory 0.010 (-0.016-0.037) 0.43  -0.67 0.50 
Motor function 0.029 (0.001-0.057) 0.04  0.69 0.49 
Processing speed 0.017 (-0.010-0.043) 0.21  0.76 0.45 
Global  0.026 (0.006-0.046) 0.01 
 
 1.34 0.18 
       




Cognitive domain Estimate  (95% CI) p-value  t199 p-value 
Attention 0.099 (0.013-0.187) 0.03  -1.67 0.09 
Executive function 0.073 (0.008-0.139) 0.03  -0.62 0.54 
Memory 0.035 (-0.028-0.097) 0.27  -0.53 0.60 
Motor function 0.079 (0.013-0.144) 0.02  1.25 0.21 
Processing speed 0.092 (0.031-0.152) <0.01  -0.41 0.68 





Multiple linear regression estimates for grey matter volume and fractional anisotropy 
by cognitive domain adjusted for age, intracranial volume and scanner type. In 
addition, HIV-status and neuroimaging measure interaction statistics for each 
cognitive domain. 
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Figures titles and legends 
 




P-values calculated using the Wilcoxon rank sum test. 
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Figure 2. Voxelwise analyses of volumetric and diffusion measures.  
 
 
A) Grey matter voxel based morphometry group comparison. Areas with significantly 
(p<0.05) lower grey matter volume coloured by t-statistic (red/yellow) - corrected for 
multiple comparisons and adjusted for age, intracranial volume and scanner. 
Significant differences are overlaid on the Montreal Neurological Institute 152 T1 
brain image. 
 
B) White matter tract-based spatial statistics group comparison. Areas of significantly 
(p<0.05) lower fractional anisotropy (FA), higher mean diffusivity (MD) and higher 
radial diffusivity (RD) are coloured red-yellow, light blue and dark blue by t-statistic 
respectively - corrected for multiple comparisons and adjusted for age, intracranial 
volume and scanner. Significant differences overlaid on the white matter skeleton 
(green) and the mean fractional anisotropy image (greyscale). 
 
Abbreviations: FA: fractional anisotropy; MD: mean diffusivity; RD: radial 
diffusivity. 
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Figure 3. Correspondence between HIV-associated brain injury and regions correlated 
with cognitive function.  
 
A) Voxel-wise analysis depicting regions of grey matter volume significantly lower in 
the HIV-positive group vs. HIV-negative group (red), positively correlated with 
cognitive function T-scores (green) and overlap (yellow) - corrected for multiple 
comparisons and adjusted for age, intracranial volume and scanner. Statistical images 
overlaid on MNI 152 T1. There were no voxelwise associations between language T-
scores and grey matter volume. 
 
A) Voxel-wise analyses depicting regions of fractional anisotropy significantly lower 
in the HIV-positive group vs. HIV-negative group (red), positively correlated with 
cognitive function T-scores (green) and overlap (yellow) - corrected for multiple 
comparisons and adjusted for age, intracranial volume and scanner. Statistical images 
overlaid on the mean fractional anisotropy image. There were no voxelwise 
associations between language or memory T-scores and FA. 
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Figure 4. K-means cluster analysis results by HIV-status. 
 
A) Visualisation of the correlation matrices for the regions of cortical and subcortical 
grey matter volume (Harvard-Oxford atlas) and white matter fractional anisotropy 
(International Consortium of Brain Mapping DTI-81 white matter labels) used in the 
k-means clustering analysis for the HIV-positive and HIV-negative groups. The 
correlation coefficient is represented by the colour of the box (scale to the right of the 
figure).  
B) Principle component plot showing the separation of the clusters based on the k-
means clustering analysis of parcellated grey matter and mean fractional anisotropy 
data for the HIV-negative controls on the left (circles) and HIV-positive participants 
on the right (triangles). Cluster one (orange) had higher grey matter volume and 
higher fractional anisotropy for each region whereas cluster two (green) had lower 
grey matter volume and lower fractional anisotropy for each region. HIV-positive 
individuals were more likely to be members of the lower grey matter volume and 
lower fractional anisotropy cluster (odds ratio [95% confidence intervals]: 2.74 [1.53-
4.98]). 
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Figure 5. K-means cluster analysis and cognitive function. 
 
Jitterplot of cognitive domain T-scores grouped by k-means cluster analysis. Cluster 
one represents the cluster with higher total grey matter volume (GMV) and higher 
mean white matter skeleton fractional anisotropy (FA) in each region whereas cluster 
two represents the cluster with lower total grey matter volume and lower mean white 
matter skeleton fractional anisotropy in each region. Black lines represent medians for 
each cluster with p-values calculated using the Wilcoxon rank sum test. 
 
